Backfilling cohorts in phase I dose-escalation studies

A phase I study of LY3410738, a first-in-class covalent inhibitor of mutant IDH1 in cholangiocarcinoma and other advanced solid tumors.

(2021) James Michael Pauff et al.   JOURNAL OF CLINICAL ONCOLOGY

Using an Interaction Parameter in Model-Based Phase I Trials for Combination Treatments? A Simulation Study

(2021) Pavel Mozgunov et al.   International Journal of Environmental Research and Public Health

Controlled backfill in oncology dose-finding trials

(2021) Hakim-Moulay Dehbi et al.   Contemporary Clinical Trials

How to design a dose-finding study using the continual reassessment method

(2019) Graham M. Wheeler et al.   BMC Medical Research Methodology

First-in-Human Phase I Study of the Activin A Inhibitor, STM 434, in Patients with Granulosa Cell Ovarian Cancer and Other Advanced Solid Tumors

(2019) Jessica J Tao et al.   CLINICAL CANCER RESEARCH

Phase I dose escalation of H3B-6545, a first-in-class highly Selective ERα Covalent Antagonist (SERCA), in women with ER-positive, HER2-negative breast cancer (HR+ BC).

(2019) Erika Paige Hamilton et al.   JOURNAL OF CLINICAL ONCOLOGY

Adaptive Dose-Finding Studies: A Review of Model-Guided Phase I Clinical Trials

(2014) Alexia Iasonos et al.   JOURNAL OF CLINICAL ONCOLOGY

Bayesian optimal interval designs for phase I clinical trials

(2014) Suyu Liu et al.   JOURNAL OF THE ROYAL STATISTICAL SOCIETY SERIES C-APPLIED STATISTICS

New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)

(2008) E.A. Eisenhauer et al.   EUROPEAN JOURNAL OF CANCER

Critical aspects of the Bayesian approach to phase I cancer trials

(2008) Beat Neuenschwander et al.   STATISTICS IN MEDICINE